MACE and VTE from 9 (6 RA, 2 PsA, 1 AS) RCTs w/ UPA.
6000+ pts received UPA 40-50% w/ > or = 2 BL CV risk factors.
41 MACE UPA 15mg RA-PsA group & 2 fatal VTE UPA 15mg RA group.
Overlapping confidence intervals w/ADA & MTX.
t.co/7xtZlDIkVu
Abs#0510 #ACR22 @Rheumnow
MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis - ACR Meeting Abstracts
6000+ pts received UPA 40-50% w/ > or = 2 BL CV risk factors.
41 MACE UPA 15mg RA-PsA group & 2 fatal VTE UPA 15mg RA group.
Overlapping confidence intervals w/ADA & MTX.
t.co/7xtZlDIkVu
Abs#0510 #ACR22 @Rheumnow
